3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
703
Carcinoma, Renal Cell
231
Urinary Bladder Neoplasms
202
Carcinoma, Transitional Cell
117
Breast Neoplasms
99
Kidney Neoplasms
92
Neoplasms
84
Carcinoma, Non-Small-Cell Lung
83
Ovarian Neoplasms
80
Melanoma
80
Colorectal Neoplasms
72
Neoplasm Metastasis
68
Non-Muscle Invasive Bladder Neoplasms
58
Lung Neoplasms
56
Pancreatic Neoplasms
48
Sarcoma
45
Endometrial Neoplasms
43
Stomach Neoplasms
42
Uterine Cervical Neoplasms
40
Carcinoma, Hepatocellular
34
Adenocarcinoma
34
Wilms Tumor
33
Esophageal Neoplasms
31
Squamous Cell Carcinoma of Head and Neck
30
Triple Negative Breast Neoplasms
29
Head and Neck Neoplasms
29
Metastatic Castration-resistant Prostate Cancer
25
Testicular Neoplasms
24
Neuroblastoma
23
Colonic Neoplasms
23
Interventions
Standard of Care
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Progressive Metastatic Castrate Resistant Prostate Cancer
×
Genitourinary
×
90 days
×
Clear all
NCT07206056
2026-06-03
TulmiSTAR-01
Novartis
Phase 1/2
Recruiting
188 enrolled